Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $551.8 million.

  • Syndax Pharmaceuticals' Liabilities and Shareholders Equity rose 2958.61% to $551.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 billion, marking a year-over-year increase of 2209.19%. This contributed to the annual value of $724.8 million for FY2024, which is 1826.39% up from last year.
  • Syndax Pharmaceuticals' Liabilities and Shareholders Equity amounted to $551.8 million in Q3 2025, which was up 2958.61% from $596.1 million recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $724.8 million in Q4 2024 and a low of $239.5 million during Q3 2021
  • For the 5-year period, Syndax Pharmaceuticals' Liabilities and Shareholders Equity averaged around $462.1 million, with its median value being $449.7 million (2021).
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Liabilities and Shareholders Equity soared by 16596.17% in 2021, and later soared by 612.71% in 2023.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Liabilities and Shareholders Equity stood at $449.7 million in 2021, then grew by 10.58% to $497.2 million in 2022, then grew by 23.26% to $612.9 million in 2023, then rose by 18.26% to $724.8 million in 2024, then decreased by 23.87% to $551.8 million in 2025.
  • Its Liabilities and Shareholders Equity was $551.8 million in Q3 2025, compared to $596.1 million in Q2 2025 and $640.7 million in Q1 2025.